Sign up to save your podcasts
Or
Share Mike Teiler – Innovating Type 1 Diabetes Treatment
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Mike Teiler – Innovating Type 1 Diabetes Treatment
My son was diagnosed with type 1 diabetes at the age of 13.
Which is why this episode is very close to my heart. There are big life-altering challenges for the patient and their family in managing type 1 diabetes. With limitations to the current insulin therapies that make the work of my guest in the episode, Mike Teiler, all the more important.
Mike is the Chief Pharmaceutical Officer at LeviCure, a startup focused on new approaches to type 1 diabetes. In this episode we discuss the difference between type 1 and type 2 diabetes. And explore the development of LeviCure's triple therapy, which combines three existing drugs to improve glycaemic control and potentially achieve remission in type 1 diabetes patients.
A therapy that has shown promising results in both recent onset and established patients. We discuss the potential of repurposing existing drugs for the treatment of type 1 diabetes. As well as the funding required and the clinical trial process that will be undertaken to be able to launch the therapy.
“Many of them completely stopped insulin injections.” – Mike Teiler
You’ll hear about:
01:10 - The difference between type & type 2 diabetes
04:03 - The lifechanging nature of type 1 diabetes
06:40 - The LeviCure story
11:16 - The effect of weening people off of insulin
15:08 - Oral drugs that could replace insulin
18:48 - Disentangling the honeymoon effect
20:15 - The effects on established patients
25:02 - The pharmaceutical benefits of this therapy
27:58 - The intellectual property perspective
30:43 - The democratic nature of these new therapies
34:15 - What are the clinical phases?
41:08 - Making sure the therapies hit the target
43:44 - The fundraising needed
Follow Mike:
LinkedIn - https://www.linkedin.com/in/miketeiler/
LeviCure on LinkedIn - https://www.linkedin.com/company/levicure-ltd/
LeviCure - https://www.levicure.com/
Connect with me:
LinkedIn: https://www.linkedin.com/in/markdavison100/
Grant Instruments: https://www.grantinstruments.com/
Grant Instruments on LinkedIn: https://www.linkedin.com/company/grant-instruments-cambridge-ltd/
View all episodes
By Mark DavisonMy son was diagnosed with type 1 diabetes at the age of 13.
Which is why this episode is very close to my heart. There are big life-altering challenges for the patient and their family in managing type 1 diabetes. With limitations to the current insulin therapies that make the work of my guest in the episode, Mike Teiler, all the more important.
Mike is the Chief Pharmaceutical Officer at LeviCure, a startup focused on new approaches to type 1 diabetes. In this episode we discuss the difference between type 1 and type 2 diabetes. And explore the development of LeviCure's triple therapy, which combines three existing drugs to improve glycaemic control and potentially achieve remission in type 1 diabetes patients.
A therapy that has shown promising results in both recent onset and established patients. We discuss the potential of repurposing existing drugs for the treatment of type 1 diabetes. As well as the funding required and the clinical trial process that will be undertaken to be able to launch the therapy.
“Many of them completely stopped insulin injections.” – Mike Teiler
You’ll hear about:
01:10 - The difference between type & type 2 diabetes
04:03 - The lifechanging nature of type 1 diabetes
06:40 - The LeviCure story
11:16 - The effect of weening people off of insulin
15:08 - Oral drugs that could replace insulin
18:48 - Disentangling the honeymoon effect
20:15 - The effects on established patients
25:02 - The pharmaceutical benefits of this therapy
27:58 - The intellectual property perspective
30:43 - The democratic nature of these new therapies
34:15 - What are the clinical phases?
41:08 - Making sure the therapies hit the target
43:44 - The fundraising needed
Follow Mike:
LinkedIn - https://www.linkedin.com/in/miketeiler/
LeviCure on LinkedIn - https://www.linkedin.com/company/levicure-ltd/
LeviCure - https://www.levicure.com/
Connect with me:
LinkedIn: https://www.linkedin.com/in/markdavison100/
Grant Instruments: https://www.grantinstruments.com/
Grant Instruments on LinkedIn: https://www.linkedin.com/company/grant-instruments-cambridge-ltd/